🇺🇸 FDA
Patent

US 9452182

Collateral gene inactivation biomarkers and targets for cancer therapy

granted A61KA61K31/191A61K31/198

Quick answer

US patent 9452182 (Collateral gene inactivation biomarkers and targets for cancer therapy) held by The Board of Regents of the University of Texas System expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/191, A61K31/198, A61K31/35, A61K31/352